Charles Porter

Dr. Charles Porter

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JHJoerg Herrmann
Joerg Herrmann
DLDaniel Lenihan
Daniel Lenihan
SASaro Armenian
Saro Armenian
ABAna Barac
Ana Barac
ABAnne Blaes
Anne Blaes
PVPeter Valent
Peter Valent
The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which can have profound implications on prognosis. To that effect, many studies have assessed CV toxicities in patients undergoing various types of cancer therapies; however, direct comparisons have proven difficult due to lack of uniformity in CV toxicity endpoints. Similarly, in clinical practice, there can be substantial differences in the understanding of what constitutes CV toxicity, which can lead to significant variation in patient management and outcomes. This document addresses these issues and provides consensus definitions for the most commonly reported CV toxicities, including cardiomyopathy/heart failure and myocarditis, vascular toxicity, and hypertension, as well as arrhythmias and QTc prolongation. The current document reflects a harmonizing review of the current landscape in CV toxicities and the definitions used to define these. This consensus effort aims to provide a structure for definitions of CV toxicity in the clinic and for future research. It will be important to link the definitions outlined herein to outcomes in clinical practice and CV endpoints in clinical trials. It should facilitate communication across various disciplines to improve clinical outcomes for cancer patients with CV diseases.

20 September 2022 in JACC: Cardiooncology
Verified
Journal Article
Open access
CPCharles Porter
Charles Porter
TATariq U. Azam
Tariq U. Azam
DMDivyanshu Mohananey
Divyanshu Mohananey
RKRohit Kumar
Rohit Kumar
JCJian Chu
Jian Chu
TOTochukwu Okwuosa
Tochukwu Okwuosa
The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targeted and immunologic cancer therapies beyond the usual chemotherapy and/or radiation therapy. Often, potentially cardiotoxic anticancer treatment is necessary in patients with baseline cardiovascular disease. Moreover, patients may need to continue therapy in the setting of incident cancer therapy–associated cardiotoxicity. Herein, we present and discuss the concept of permissive cardiotoxicity as a novel term that represents an essential concept in the field of cardio-oncology and among practicing cardio-oncology specialists. It emphasizes a proactive rather than reactive approach to continuation of lifesaving cancer therapies in order to achieve the best oncologic outcome while mitigating associated and potentially off-target cardiotoxicities.

1 June 2016 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
DLDaniel J. Lenihan
Daniel J. Lenihan
GHGregory Hartlage
Gregory Hartlage
JDJeanne DeCara
Jeanne DeCara
ABAnne Blaes
Anne Blaes
JFJ. Emanuel Finet
J. Emanuel Finet
JCJoseph Carver
Joseph Carver

8 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LCLei Chen
Lei Chen
RHRachel Holder
Rachel Holder
CPCharles Porter
Charles Porter
ZSZubair Shah
Zubair Shah
The toxicity of doxorubicin to the cardiovascular system often limits its benefits and widespread use as chemotherapy. The mechanisms involved in doxorubicin-induced cardiovascular damage and possible protective interventions are not well-explored. Using human aortic endothelial cells, we show vitamin D3 strongly attenuates doxorubicin-induced senescence and cell cycle arrest. We further show the protective effects of vitamin D3 are mediated by the upregulation of IL-10 and FOXO3a expression through fine modulation of pAMPKα/SIRT1/FOXO3a complex activity. These results have great significance in finding a target for mitigating doxorubicin-induced cardiovascular toxicity.

1 November 2021 in Journal of Cardiac Failure
Verified
Journal Article
Open access
TDTarun Dalia
Tarun Dalia
PAPrakash Acharya
Prakash Acharya
WCWan-Chi Chan
Wan-Chi Chan
ASAndrew J. Sauer
Andrew J. Sauer
RWRobert Weidling
Robert Weidling
ZSZubair Shah
Zubair Shah
The prognostic value of cardiopulmonary exercise testing (CPET) in patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis is unknown. This retrospective study included patients with wtATTR who underwent baseline cardiopulmonary exercise testing and were treated with tafamidis from August 31, 2018, until March 31, 2020. Univariate logistic and multivariate cox-regression models were used to predict the occurrence of the primary outcome (composite of mortality, heart transplant, and palliative inotrope initiation). A total of 33 patients were included (median age 82 years, interquartile range [IQR] 79-84 years), 84% were Caucasians and 79% were males). Majority of patients had New York Heart Association functional class III disease at baseline (67%). The baseline median peak oxygen consumption (VO2) and peak circulatory power (CP) were 11.35 mL/kg/min (IQR 8.5-14.2 mL/kg/min) and 1485.8 mm Hg/mL/min (IQR 988-2184 mm Hg/mL/min), respectively, the median ventilatory efficiency was 35.7 (IQR 31-41.2). After 1 year of follow-up, 11 patients experienced a primary end point. Upon multivariate analysis, the low peak VO2 (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.23-0.79, P = .007], peak CP (HR 0.98, 95% CI 0.98-0.99, P = .02), peak oxygen pulse (HR 0.62, 95% CI 0.39-0.97, P = .03), and exercise duration of less than 5.5 minutes (HR 5.82, 95% CI 1.29-26.2, P = .02) were significantly associated with the primary outcome. Tafamidis-treated patients with wtATTR who had baseline low peak VO2, peak CP, peak O2 pulse, and exercise duration of less than 5.5 minutes had worse outcomes.

9 September 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
WTWarren Tai
Warren Tai
GDGary C. Doolittle
Gary C. Doolittle
ZSZubair Shah
Zubair Shah
JAJames B. Atkinson
James B. Atkinson
ERElaine Russell
Elaine Russell
CPCharles Porter
Charles Porter